Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BCYC, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Naloxone | Opioid Use Disorder | Phase 4 · NCT05644587 | Terminated |
| BT1718 | Advanced Solid Tumours | Phase 1/2 · NCT03486730 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BCYC holds $469.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $45M/quarter from operations, an estimated runway of 31.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 10 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BCYC files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP Director, 10% owner · +38,000 options |
Insider | 10,018,674 | 33.35% | 2026-01-02 |
| Armistice Capital, LLC | Institution (13G, 5%+) | 3,472,000 | 11.56% | 2026-09-30 |
| LONG FOCUS CAPITAL MANAGEMENT, LLC | Institution (13G, 5%+) | 3,310,687 | 11.02% | 2026-03-31 |
| Kevin Lee CHIEF EXECUTIVE OFFICER, Director · +330,000 options |
Insider | 595,866 | 1.98% | 2026-10-02 |
| Gregory Paul Winter Director · +19,000 options |
Insider | 196,427 | 0.65% | 2026-01-02 |
| Michael Skynner CHIEF SCIENTIFIC OFFICER · +160,000 options |
Insider | 154,726 | 0.52% | 2026-10-02 |
| Alistair Milnes CHIEF OPERATING OFFICER · +100,000 options |
Insider | 136,717 | 0.46% | 2026-01-02 |
| Michael Charles Ferguson Hannay CHIEF PROD & SUPPLY CHAIN OFF · +160,000 options |
Insider | 92,561 | 0.31% | 2026-10-02 |
| Jennifer Scott Perry Chief Operating Officer · +60,000 options |
Insider | 89,602 | 0.30% | 2026-10-02 |
| Alethia Young Chief Financial Officer · +100,000 options |
Insider | 87,081 | 0.29% | 2026-01-02 |
| Travis Alvin Thompson Chief Financial Officer · +193,000 options |
Insider | 64,449 | 0.21% | 2026-10-02 |
| Janice Bourque Director · +19,000 options |
Insider | 32,500 | 0.11% | 2026-01-02 |
Share count 30,043,486 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BCYC and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →